Market Analysis and Size

Bioprosthetics are animal or human body parts or tissue used for medical purposes. This market has experienced remarkable growth. The implanted portion dissolves over time in the body, and new tissue forms in its stead. In the long run, the deteriorated component gets replaced with neotissue. As a result, not only does this replace the tissue, but it also leads to tissue regeneration, which exhibits all of the healthy properties of the tissue and stimulates angiogenesis.

Data Bridge Market Research analyses that the bioprosthetics market which was USD 4.42 billion in 2021, would rocket up to USD 10.11 billion by 2029, and is expected to undergo a CAGR of 10.90% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Bioprosthetics are implanted devices made from non-synthetic or natural materials. Many benefits are connected with the usage of bioprostheses, owing to their primary property of degrading and eventually being eliminated by the host body.

Bioprosthetics Market Dynamics

Drivers

• Increasing prevalence of cardiovascular disorders

The bioprosthetics market is expected to be driven by rising cases of coronary, peripheral artery disease, and other cardiovascular illnesses, as well as an increase in desire for long-term relief. Bioprosthetics are organic components derived from humans or animals that are used in medical procedures. Tissue rejuvenation is used in bioprosthetics to heal damaged tissue. The bioprosthetics market is expected to be driven by the rising prevalence of several cardiovascular illnesses and the quest for long-term relief.

• Technological advancements made in the field of healthcare

Non-biodegradable scaffolds are utilised in the construction of hybrid bioprostheses, such as hybrid tissue-engineered bioprostheses, which give excellent resistance and durability. As a result, it is frequently substituted for mechanical raw materials. The bioprosthetics industry is driven by technical advancements and investments in research and development.

• Increasing demand for technologically advanced products

The demand for bioprosthetics will increase as the number of patients suffering from cardiovascular disorders such as rheumatic heart disease, which necessitate valve replacement, grows. An unexpected shift in lifestyle habits is blamed for increased cardiovascular disorders. In addition, the market is expected to grow due to an increase in the geriatric population with cardiovascular and respiratory disorders. Rapid advancements in tissue-engineered bioprostheses will fuel industry expansion.

Opportunities

• Increasing population of older people

During the forecast period, the rising population of older persons who are more likely to have cardiac impairments and tissue damage is expected to drive demand for bioprosthetics. The latest developing technologies have evolved as a result of considerable study, testing, and clinical trials. The advancement of non-biodegradable cultured tissue scaffolds in the field of hybrid tissue-engineered bioprostheses. These hybrid tissue-engineered bioprostheses are proven to be a better option to mechanical raw materials previously used, with great resistance and durability.

Restraints/Challenges

• Need of multiple surgeries, threat of infections

People's lifestyles have evolved dramatically, and they now lead far more sophisticated and complex lives. The development of cardiac abnormalities is also linked to an unhealthy lifestyle and eating habits. The demand for bioprosthetics is expected to be fueled by an untidy lifestyle that leads to cardiac problems and tissue damage. The likelihood of infections, numerous procedures, incompatibility (tissue rejection), and the hazard of uneven skin tone and scarring after surgeries, among other problems, could operate as a restraint for this market.

This bioprosthetics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bioprosthetics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Bioprosthetics Market Scope

The bioprosthetics market is segmented on the basis of product type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Allograft
• Xenograft
• Porcine
• Bovine

Application

• Cardiovascular
• Plastic surgery and wound healing

Bioprosthetics Market Regional Analysis/Insights

The bioprosthetics market is analysed and market size insights and trends are provided by country, type and application as referenced above.

The countries covered in the bioprosthetics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the global bioprosthetics market in terms of market share during the forecast period due to growing technical innovations regarding cardiovascular and orthopaedic procedures.

Asia-Pacific bioprosthetics market is anticipated to grow at the fastest CAGR of over 10.90% during the forecast period owing to the growing patient awareness levels toward alternative treatment options and the rapidly improving healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Bioprosthetics Market Share Analysis

The bioprosthetics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bioprosthetics market.

Some of the major players operating in the bioprosthetics market are:

• LifeCell International Pvt. Ltd. (U.S)
• Edwards Lifesciences Corporation (U.S)
• LeMaitre Vascular, Inc. (U.S)
• CryoLife, Inc. (U.S)
• Labcor Laboratorios Ltd. (U.S)
• Getinge AB (Germany)
• Organogenesis, Inc. (U.S)
• Braile Biomedica (Brazil)
• Medtronic (Ireland)
• Humacyte, Inc. (U.S)
• Aortech International Plc (U.K)
• JenaValve Technology Inc. (Germany)
• Sorin Group (Italy)
• Ethicon, Inc. (U.S)
• Abbott (U.S)

SKU-68625